Clinical trials: open to volunteers, sponsored by European Organisation for Research and Treatment of Cancer - EORTC
- Lead sponsor (exact) European Organisation for Research and Treatment of Cancer - EORTC
- Status Open to volunteers
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall…
- Trial name
- PRIMALung (NCT04790253)
- Testing
- Prophylactic cranial irradiation
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ER-positive Breast Cancer, HER2-negative Breast Cancer
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse.
- Conditions
- ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
- Trial name
- TREAT ctDNA (NCT05512364)
- Testing
- Elacestrant, Tamoxifen, Letrozole 2.5mg
- Where
- 113 sites in Belgium, Cyprus and 10 more
- Volunteers
- 220 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
IDH-mutant Grade 2 or 3 Astrocytoma
Vorasidenib Maintenance for IDH Mutant Astrocytoma
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3…
- Trial name
- VIGOR (NCT06809322)
- Testing
- Vorasidenib
- Where
- 59 sites in Australia, Austria and 10 more
- Volunteers
- 468 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Muscle Invasive Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Standard treatment for patients with high-risk NMIBC (high-grade Ta, CIS, or any T1) consists of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy.
- Trial name
- BRACE (NCT06990061)
- Testing
- Radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Diagnosis of Cancer
Eortc MoBilE Device (EMBED)
This study is a longitudinal observational study that will investigate the feasibility of using mobile devices for the assessment of HRQoL and physical activity in adult cancer patients undergoing treatment.
- Trial name
- EMBED (NCT07711080)
- Volunteers
- 137 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uveal Melanoma
Adjuvant Tebentafusp in High Risk Ocular Melanoma
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting.
- Trial name
- ATOM (NCT06246149)
- Testing
- Tebentafusp
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 290 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer…
- Trial name
- SPECTA (NCT02834884)
- Testing
- RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen
- Where
- 136 sites in Austria, Belgium and 18 more
- Volunteers
- 4,975 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Meningioma
177Lu-DOTATATE for Recurrent Meningioma
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation.
- Trial name
- LUMEN-1 (NCT06326190)
- Testing
- Local standard of Care, 177Lu-DOTATATE
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Clear Cell Renal Cell Carcinoma
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy.
- Trial name
- RENALUT (NCT06783348)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally.
- Trial name
- NCT07234877
- Testing
- Ivonescimab, Carboplatin, Pemetrexed
- Where
- 26 sites in Austria, France and 6 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell…
- Trial name
- PROLoNg (NCT05815927)
- Testing
- Pembrolizumab, stereotattic ablation radiotherapy (SABR)
- Where
- 30 sites in Belgium, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
AML (Acute Myeloid Leukemia)
FLT3-ITD Targeted Therapy in Fit AML Patients
This international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction…
- Trial name
- FIT-AML (NCT07425808)
- Testing
- Gilteritinib, Venetoclax, Azacitidine (AZA)
- Volunteers
- 230 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioma, Glioneuronal Tumor
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on…
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
- Trial name
- NCT05259605
- Testing
- Observational
- Where
- 42 sites in Austria, Belgium and 10 more
- Volunteers
- 1,650 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce…
- Trial name
- NCT05974774
- Testing
- iMAB, cMAB
- Where
- 9 sites in Denmark, France and 1 more
- Volunteers
- 1,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
GastroEsophageal Cancer
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
This is an open-label,multi-centre, phase 1b safety and feasibility study aiming to assess the safey and feasibility of bemarituzumab plus chemiotherapy (FLOT) for the peri-operative treatment of resectable gastroesophageal…
- Trial name
- NeoBEMA (NCT06978062)
- Testing
- Bemarituzumab, FLOT
- Volunteers
- 27 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach.
- Trial name
- E²-RADIatE (NCT03818503)
- Where
- 77 sites in Austria, Belgium and 12 more
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ER+ Breast Cancer, HER2-negative Breast Cancer
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
This study is a pragmatic international, multicenter, randomized, open label 3- arm trial of standard care vs. two pharmacological interventions: duloxetine or furosemide in patients with stage I-III ER+/HER2- early breast cancer…
- Conditions
- ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- NCT06407401
- Testing
- Duloxetine 60 MG, Furosemide 40 mg, Booklet for healthy behaviors
- Volunteers
- 399 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC